Codiak BioSciences (Sarepta) vs Exopharm: CDMO Comparison
Side-by-side comparison of Codiak BioSciences (Sarepta) and Exopharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Codiak BioSciences (Sarepta) has FDA inspections on record (1); Exopharm does not yet appear in the FDA inspection database.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Codiak BioSciences (Sarepta) appears as a manufacturing partner on more matched clinical programs (16 vs 0) — a broader sponsor book.
- Composite Signal Score: Codiak BioSciences (Sarepta) 78/100 vs Exopharm 56/100 — a 22-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Codiak BioSciences (Sarepta) and Exopharm qualify as Exosome manufacturers; Codiak BioSciences (Sarepta) carries the higher composite Signal Score for Exosome programs in this comparison.
What to evaluate for Exosome programs
Both Codiak BioSciences (Sarepta) and Exopharm qualify as Exosome CDMOs. When choosing between them for Exosome programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
Cell source & scale
Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand.
Isolation & purification
Isolation method (tangential-flow filtration, chromatography) drives yield, purity, and scalability. Ask how it performs at your target scale.
Characterization & potency
EV characterization (particle count, size, cargo, identity) and potency assays are still maturing — look for established, qualified methods.
Regulatory track record
Cross-check FDA 483 history and EMA/MHRA GMP coverage — both shown above and on each profile.
Frequently asked: Codiak BioSciences (Sarepta) vs Exopharm
Which has the stronger FDA inspection record, Codiak BioSciences (Sarepta) or Exopharm?
Both Codiak BioSciences (Sarepta) and Exopharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Codiak BioSciences (Sarepta) has 1 FDA inspection on record; Exopharm has 0.
Which is more active in clinical-stage manufacturing — Codiak BioSciences (Sarepta) or Exopharm?
Codiak BioSciences (Sarepta) is matched to 16 ClinicalTrials.gov records as a manufacturing partner; Exopharm is matched to 0. Higher counts indicate broader sponsor exposure but say nothing about approved-product track record — pair this number with each CDMO's profile page for context.
Which is better for Exosome manufacturing — Codiak BioSciences (Sarepta) or Exopharm?
Both Codiak BioSciences (Sarepta) and Exopharm are tagged as Exosome CDMOs in our directory, so both are credible options for Exosome programs. The most important differentiator for Exosome selection is typically cell source & scale: Confirm the producer cell source and whether culture is suspension-adapted for the volumes EV yields demand. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Codiak BioSciences (Sarepta) carries a Signal Score of 78/100 and Exopharm carries 56/100 — a substantial lead for Codiak BioSciences (Sarepta). The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →